Steris (STE) Releases FY 2019 Earnings Guidance

Steris (NYSE:STE) updated its FY 2019 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $4.74-4.84 for the period, compared to the Thomson Reuters consensus estimate of $4.70. The company issued revenue guidance of $2.751-2.751 billion, compared to the consensus revenue estimate of $2.73 billion.Steris also updated its FY19 guidance to $4.74-4.84 EPS.

Several equities analysts have recently weighed in on the company. KeyCorp lifted their price target on Steris from $115.00 to $120.00 and gave the company an overweight rating in a research report on Thursday, August 9th. Stephens reiterated a buy rating and issued a $125.00 price target on shares of Steris in a research report on Thursday, August 9th. JMP Securities lifted their price target on Steris from $113.00 to $125.00 and gave the company a market outperform rating in a research report on Thursday, August 9th. Finally, Zacks Investment Research upgraded Steris from a sell rating to a hold rating in a research report on Thursday, September 20th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $100.86.

Steris stock traded up $0.81 during midday trading on Thursday, hitting $120.70. 521,422 shares of the company’s stock were exchanged, compared to its average volume of 373,073. Steris has a 52-week low of $82.88 and a 52-week high of $121.67. The company has a quick ratio of 2.02, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. The stock has a market cap of $9.93 billion, a price-to-earnings ratio of 29.08 and a beta of 1.03.

Steris (NYSE:STE) last posted its earnings results on Tuesday, November 6th. The medical equipment provider reported $1.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.02. Steris had a return on equity of 12.15% and a net margin of 11.72%. The business had revenue of $679.00 million during the quarter, compared to analysts’ expectations of $659.14 million. During the same period in the previous year, the business earned $0.94 earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. On average, research analysts anticipate that Steris will post 4.71 earnings per share for the current year.

In related news, VP Karen L. Burton sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $114.39, for a total transaction of $148,707.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.38% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Further Reading: Inflation

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with's FREE daily email newsletter.

Leave a Reply